Navigating Obesity Treatment: Bariatric Surgery, GLP-1 Medications, or Both?

Author: nwwls.com 

Obesity remains a significant public health challenge, affecting over 42% of adults in the United States. The rise of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, has introduced new avenues for weight management. Concurrently, bariatric surgery continues to be a cornerstone treatment for severe obesity. Recent studies have compared the efficacy, cost-effectiveness, and long-term outcomes of these interventions, prompting discussions about the optimal approach to obesity treatment.

Efficacy of Bariatric Surgery vs. GLP-1 Medications

Bariatric surgery, including procedures like sleeve gastrectomy and Roux-en-Y gastric bypass, has consistently demonstrated substantial and sustained weight loss. Patients typically experience a 25% to 33% reduction in body weight post-surgery. In contrast, GLP-1 medications yield approximately 15% to 20% weight loss. While both interventions improve metabolic health, the magnitude of weight loss is generally greater with surgery.

Cost-Effectiveness Considerations

The financial implications of obesity treatments are crucial for both patients and healthcare systems. A study presented at the American College of Surgeons meeting highlighted that bariatric surgery is more cost-effective over the long term compared to GLP-1 medications. The analysis considered treatment costs and the number of healthy life years gained, concluding that surgery offers better value, especially when combined with medications.

Long-Term Outcomes and Sustainability

Sustaining weight loss is a common challenge in obesity management. Bariatric surgery has shown durable results, with patients maintaining significant weight loss over a decade. Conversely, weight regain is a concern with GLP-1 medications, particularly upon discontinuation. Studies indicate that patients may regain up to 12% of their body weight within a year after stopping these drugs. This underscores the importance of long-term adherence and lifestyle modifications when using pharmacotherapy.

Health Benefits Beyond Weight Loss

Beyond weight reduction, both bariatric surgery and GLP-1 medications confer additional health benefits. Bariatric surgery has been associated with a 62% reduction in mortality among patients with obesity and type 2 diabetes. It also decreases the risk of developing nonalcoholic fatty liver disease (NAFLD) more effectively than GLP-1 medications. On the other hand, GLP-1 receptor agonists have demonstrated cardioprotective effects and potential benefits in treating conditions like polycystic ovary syndrome and binge eating disorder.

Combining Therapies: A Synergistic Approach

Emerging evidence suggests that combining bariatric surgery with GLP-1 medications may enhance weight loss outcomes. A review of studies found that adding liraglutide to endoscopic bariatric therapy or surgery resulted in greater weight loss compared to surgery alone. This combination approach may offer a promising strategy for patients requiring more intensive interventions.

Patient Selection and Personalized Treatment

Selecting the appropriate treatment requires a personalized approach, considering factors such as BMI, comorbidities, patient preferences, and potential risks. Bariatric surgery is typically recommended for individuals with a BMI ≥40 or ≥35 with obesity-related health conditions. GLP-1 medications are approved for patients with a BMI ≥30 or ≥27 with comorbidities. Shared decision-making between patients and healthcare providers is essential to determine the most suitable intervention.

Conclusion

The management of obesity is multifaceted, with both bariatric surgery and GLP-1 medications playing vital roles. While surgery offers more substantial and sustained weight loss, medications provide a less invasive option with additional metabolic benefits. Combining these therapies may further optimize outcomes for certain patients. Ultimately, individualized treatment plans, informed by clinical evidence and patient preferences, are key to effective obesity management.

This blog post is based on the article “Weight-Loss Surgery Instead of GLP-1s? Or Are Both Best?” by Kathleen Doheny, published on Medscape on April 11, 2025. Available at: https://www.medscape.com/viewarticle/weight-loss-surgery-instead-glp-1s-or-are-both-best-2025a10008ol

Photo Credit: FreePik.com